AstraZeneca’s Tozorakimab Delivers Third Positive Phase III Result in COPD

The latest announcement is out from AstraZeneca ( (GB:AZN) ).

AstraZeneca reported that its IL-33-targeting biologic tozorakimab met the primary endpoint in the Phase III MIRANDA trial in chronic obstructive pulmonary disease, marking the third positive pivotal study for the drug in COPD. The therapy, given every two weeks on top of standard inhaled care, produced a statistically significant and clinically meaningful reduction in annualised moderate-to-severe exacerbations in former smokers and in the broader patient population, including current smokers and across all eosinophil levels and lung-function stages.

The MIRANDA data, which showed a generally favourable safety profile consistent with earlier studies, will be submitted to regulators and presented at an upcoming medical meeting. Combined with positive OBERON and TITANIA results using a four-week regimen and ongoing long-term PROSPERO follow-up, the findings strengthen tozorakimab’s profile as a potential first-in-class biologic for COPD, a condition affecting nearly 400 million people and remaining a major cause of death despite current standard-of-care therapies.

Tozorakimab’s dual inhibition of reduced and oxidised IL-33 suggests it may address underlying inflammatory and mucus-related drivers of COPD exacerbations, potentially offering a differentiated option in a market where many patients still exacerbate on existing treatments. The drug’s broader development in severe viral lower respiratory tract disease and asthma, along with previous U.S. Fast Track designations, signals strategic importance for AstraZeneca’s respiratory pipeline and could enhance its competitive position in high-growth respiratory biologics if regulatory submissions succeed.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £16500.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Spark’s Take on AZN Stock

According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.

The score is driven primarily by strong underlying financial performance and a constructive earnings outlook (growth guidance and pipeline progress). This is tempered by valuation (P/E ~30), recent free-cash-flow variability, and technical signals that appear overextended despite the broader uptrend.

To see Spark’s full report on AZN stock, click here.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company focused on the discovery, development and commercialisation of prescription medicines in oncology, rare diseases and biopharmaceuticals, including cardiovascular, renal and metabolism, and respiratory and immunology. Headquartered in Cambridge, U.K., it is an established leader in respiratory care with a 50-year heritage and a growing portfolio of inhaled medicines, biologics and new modalities targeting immune-mediated and chronic respiratory diseases.

The company positions Respiratory & Immunology as a key growth driver, aiming to address significant unmet needs in chronic, often debilitating conditions such as COPD and asthma. Its strategic ambition is to deliver life-changing medicines that help eliminate COPD as a leading cause of death, prevent asthma attacks and achieve clinical remission in immune-mediated diseases, reinforcing its competitive stance in high-value specialty therapeutics.

Average Trading Volume: 2,685,494

Technical Sentiment Signal: Buy

Current Market Cap: £229B

Learn more about AZN stock on TipRanks’ Stock Analysis page.